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Abstract
We aimed to identify novel molecular prognostic markers to better predict relapse risk estimate for children with
high-risk (HR) metastatic neuroblastoma (NB). We performed genome- and/or transcriptome-wide analyses of 129
stage 4 HR NBs. Children older than 1 year of age were categorized as “short survivors” (dead of disease within
5 years from diagnosis) and “long survivors” (alive with an overall survival time ≥ 5 years). We reported that
patients with less than three segmental copy number aberrations in their tumor represent a molecularly defined
subgroup with a high survival probability within the current HR group of patients. The complex genomic pattern is a
prognostic marker independent of NB-associated chromosomal aberrations, i.e., MYCN amplification, 1p and 11q
losses, and 17q gain. Integrative analysis of genomic and expression signatures demonstrated that fatal outcome
is mainly associated with loss of cell cycle control and deregulation of Rho guanosine triphosphates (GTPases)
functioning in neuritogenesis. Tumors with MYCN amplification show a lower chromosome instability compared
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to MYCN single-copy NBs (P = .0008), dominated by 17q gain and 1p loss. Moreover, our results suggest that the
MYCN amplification mainly drives disruption of neuronal differentiation and reduction of cell adhesion process
involved in tumor invasion and metastasis. Further validation studies are warranted to establish this as a risk strat-
ification for patients.
Neoplasia (2012) 14, 823–832
Introduction
Neuroblastoma (NB) is the second most common solid tumor in
children with a markedly heterogeneous clinical behavior, varying
from spontaneous regression to rapid progression [1]. About 40%
of children onset with high-risk (HR) disseminated disease. The cur-
rent therapies have led to a modest improvement in long-term survival
rates of this group of patients [2–4], despite intensified therapeutic
regimens [5]. A poor rate survival is frequently observed in patients
more than 1 year of age, mainly because of poor responses or disease
relapse in primary and metastatic sites, particularly bone marrow.
Moreover, about 40% of survivors with advanced NB have sequelae
of aggressive multimodal therapies, i.e., endocrine disturbances, cata-
racts, hypertension, bronchiolitis, blindness, peripheral neuropathy,
nonfunctioning kidney, cholelithiasis, and thyroid nodules. Hence, a
risk-adapted therapy according to disease status and molecular profile
may decrease incidence of cytotoxic deaths because of high-dose ther-
apy and morbidity among surviving patients.
Patient’s age, stage,MYCN oncogene amplification, histology, and
ploidy of tumor are associated with poor prognosis [1]. In the last
decades, microarray-based high-throughput studies identified genome
and transcriptome signatures that predict patient outcome [6–15].
Tumors with near-triploid karyotypes and numerical aberrations (i.e.,
whole-chromosome gains and losses) have a good prognosis, whereas
near-diploid or near-tetraploid tumors with segmental rearrangements,
including deletions of parts of chromosome arms 1p or 11q, gain of
17q, andMYCN amplification, have a poor prognosis [16,17]. Further-
more, a 59-gene expression (GE) signature proved to be helpful as an
accurate outcome predictor in patients with NB [18,19].
Recently, the application of a pan-genomic approach has been vali-
dated in the ongoing multicenter Low- and Intermediate-Risk Neuro-
blastoma Study [20]. The treatment stratification in the Low- and
Intermediate-Risk Neuroblastoma Study is based on recent trials, sug-
gesting that the risk of relapse in patients with MYCN not amplified
low-risk tumors may be defined by the presence of any structural ge-
netic abnormalities [21]. By contrast, for patients with stage 4 NBmore
than 1 year of age, the MYCN amplification and other biomarkers fail
in predicting risk of progression/recurrence.
Previously, Bilke et al. [14] reported that whole chromosome alter-
ations predict survival in stage 4 NBs without MYCN amplification.
However, this was a pilot study and no further validations established
this risk stratification for these patients.
The present study is the largest one performed on children older
than 1 year of age at diagnosis with stage 4 NB and with the longest
follow-up time as yet. We describe the results of an integrated genomic
and RNA analysis using both array-based comparative genomic hybrid-
ization (aCGH) and GE profiling in stage 4 NB tumors of children
older than 1 year of age at diagnosis. We also investigated the role of
MYCN oncogene amplification in disease progression of these patients.
Materials and Methods
Tumor Samples
Tumor specimens were collected at the onset of disease from 129
patients who were diagnosed with a primary NB between 1988 and
2006. The study was approved by the Institutions’ Ethical Committees.
All patients were classified as stage 4 according to the International
Neuroblastoma Staging System [22], and they were older than 1 year
of age at time of diagnosis (average age, 47 months). Regarding the
clinical course, patients were categorized into two subgroups, namely,
“short survivors” (dead of disease within 60 months from diagnosis;
deaths because of toxicity were censored) and “long survivors” [alive
with an overall survival (OS) time≥ 60 months]. No significant differ-
ences over time were recorded in OS of patients in relation to enroll-
ment year (data not shown). Patients’ and tumor characteristics are
summarized in Table W1.
Analyses were performed in cohorts of patients defined as follows:
1) For aCGH profiling, all patients with available genomic tumor
DNA were selected (total 91: 55 Italian and 36 German patients;
short survivors, 46; long survivors, 45). Median age of patients at
diagnosis was 43 months. The median follow-up of alive patients
was 100 months (range, 61–164 months) and median event-free
survival (EFS) time was 96 months (range, 22–164 months). None
but three patients of the long-survivor group had relapse or progres-
sion of disease. The short survivors showed a median follow-up of
22 months (range, 1–57 months) and a median EFS of 15 months
(range, 1–40 months). Amplification of MYCN oncogene was pres-
ent in tumors of 22 short- and 4 long-surviving patients. 2) For GE
profiling, we selected all available tumors from the previous study by
Oberthuer et al. [23], which fitted to the clinical criteria described
above (total 73: short survivors, 50; long survivors, 23). Median age
at diagnosis was 54 months. The median follow-up of alive patients
was 93 months (range, 60–156 months) and median EFS time was
90 months (range, 7–156 months). The short-survivor group showed
amedian follow-up of 28months and amedian EFS time of 16months.
Amplification of MYCN oncogene was present in tumors of 20 short-
and 2 long-surviving patients.
All tumor samples were classified as Schwannian stroma-poor NB
according to the International Neuroblastoma Pathology Committee
[24], and they have at least 60% of neuroblasts.
Array-based Comparative Genomic Hybridization
High-resolution aCGH was performed using either 44K or 105K
oligonucleotide microarrays (Agilent Technologies, Santa Clara, CA)
as described elsewhere [17,25]. Images were extracted by Feature
Extraction 9.5 and analyzed by CGH Analytics 3.5.14 software
(Agilent Technologies), as specified previously [26]. Fisher exact test
[27] was used to select individual chromosomes showing nonrandom
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associations between groups and aberrations and to select individual
chromosomes showing nonrandom associations among groups and
aberrations. Chromosomes with P values smaller than .05 after
Benjamini-Hockberg multiple comparison correction were selected.
Minimal common regions (MCRs) were defined as loci with signifi-
cant copy number aberrations (CNAs) in all samples. The aCGH data
have been deposited in Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) and they are available by Gene Expression Omnibus
Series Accession Nos. GSE14109, GSE25771, and GSE35953 (for
details, see Table W1).
GE Profiling
GE profiling experiments were carried out using a customized
NB-related oligonucleotide microarray (Agilent Technologies) that
comprised 10,163 probes covering 8155 Unigene clusters [23,28].
Expression profiles were analyzed as described elsewhere [26]. Micro-
array data are available on Array Express database (http://www.ebi.ac.
uk/arrayexpress; Accession Nos. E-TABM-38 and E-MTAB-161).
Integrated Copy Number and Expression Analyses
We used two approaches to identify genes whose transcription levels
were potentially affected by DNA alterations. In a “targeted study,” we
identified the significant targeted genes (STGs) differentially expressed
among NB groups [false discovery rate (FDR) < 0.05], located in the
most frequent aberrant chromosome region, and concordant to the
corresponding CNAs, i.e., we selected overexpressed and under-
expressed genes located in a chromosome region of gain and loss, respec-
tively. In a “correlated study,” we identified the genes with expression
levels correlated withMCRs but not necessarily with a significant differ-
ential expression in all NBs. For this purpose, chromosome coordinates
of all probe sets were extracted from Feature Extraction export files by
R scripts andwe selected those probe sets located inMCRand concordant
to the corresponding CNAs, i.e., we selected those probe sets located in a
region of gain or loss and overexpressed or underexpressed, respectively.
Statistical and Bioinformatics Analyses
MedCalc (Mariakerke, Belgium) software was used for statistical
analyses. Mann-Whitney and Fisher exact tests compared the fre-
quency of CNA between long- and short-surviving individuals. All
significance tests were two tailed. To analyze the effect of changing
the chromosome aberration number threshold providing the best
separation between long and short survivors, we dichotomized the
number of CNAs according to receiver operating characteristic (ROC)
curves [29]. These threshold values were employed in subsequent
survival analyses.
The OS was defined as the time elapsed from diagnosis to cancer-
related death or to the date of the last follow-up if the patient sur-
vived. Patients who survived were censored at the last date they were
reported to be alive. The EFS was calculated from diagnosis to the
date of tumor progression or relapse or to the date of the last follow-
up if no event occurred. Survival curves were computed according to
the Kaplan-Meier method. The Cox proportional hazards regression
model was used to study in multivariate settings the effect of the
known prognostic markers in NB (MYCN amplification, 1p and
11q losses, and 17q gain) as potential confounders. An enter selection
approach was chosen and only variables with P < .05 were retained in
the model.
Gene Ontology and Canonical Pathway Analyses
Functional annotation analyses were performed by Database for
Annotation, Visualization and Integrated Discovery Bioinformatics
Resources (http://david.abcc.ncifcrf.gov/) [30]. A Gene Ontology
(GO) category was considered statistically significant at significance
threshold set on P < .05. Functional annotation analyses were per-
formed by taking into account underexpressed and overexpressed
groups separately.
Results
Specific Genomic Aberrations Characterize
Clinical HR NB Subgroups
First, we investigated CNAs in tumors of long- and short-surviving
patients. For this purpose, tumors with MYCN amplification were
intentionally excluded from the analysis because of their potential
bias. According to this criterion, 65 samples (24 short and 41 long
survivors) were selected. All tumors showed CNAs (Table W1).
Tumors of long survivors showed 204 numerical aberrations (average
5.0/case; range, 0–15) and 200 segmental aberrations (average 4.9/
case; range, 0–12). The most frequent abnormalities were 7 gain
(24 of 41, 58.5%), 17q gain (23 of 41, 56%), 11q loss (19 of 41,
46%), 17 gain (17 of 41, 41.5%), 18 gain (17 of 41, 41.5%), and
2p gain (16 of 41, 39%). All tumors of short-surviving group had
at least one segmental aberration (average 9.7/case; range, 1–20).
Recurrent changes were 17q gain (22 of 24, 92%), 11q loss (15 of
24, 62.5%), 3p loss (11 of 24, 46%), 11q gain (11 of 24, 46%),
1p loss (11 of 24, 46%), 2p gain (9 of 24, 37.5%), and 11p gain
(9 of 24, 37.5%). Numerical aberrations were present with a lower
frequency in tumors of patients with an adverse clinical outcome
(average 3.2/case; range, 0–14; Figure 1, A and B), mainly represented
by gain of whole chromosome 7 (11 of 24, 45.8%). Although all
tumors were characterized by complex aberration patterns focused
on chromosomes 1, 2, 3, 11, and 17, the number of segmental alter-
ations was significantly higher (P = .0001, Mann-Whitney test) in
the short than in long survivors (Figure 1, A–C ).
Genomic instability of each tumor was also evaluated by taking
into account the number of intrachromosome segmental aberrations
(ICSAs). Our results showed that the number of ICSA was signifi-
cantly higher (P = .0005) in the short than in the long survivors
(Figure W1A).
Chromosome Aberrations Associated with MYCN
Amplification in HR NB Tumors
To investigate the association between MYCN amplification and
chromosome instability of HR NB, we compared genome profiles
of 22 MYCN-amplified [MYCN+; median follow-up of patients:
16 months (range, 1–57 months); median EFS time: 13 months
(range, 1–40 months)] and 24MYCN single-copy [MYCN−; median
follow-up of patients: 28 months (range, 6–48 months); median EFS
time: 18 months (range, 5–29 months)] tumors from short-surviving
patients. The MYCN− tumors showed a wide variety of segmental
CNAs dominated by 17q gain (22 of 24, 92%), 11q loss (15 of 24,
62.5%), 1p loss (11 of 24, 46%), 3p loss (11 of 24, 46%), and 11q
gain (11 of 24, 46%). In contrast, the MYCN+ tumors showed a less
complex segmental CNA pattern compared to theMYCN− group (P =
.0008, Mann-Whitney test; Figure 1, D–F ). The lower degree of
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genomic instability of MYCN+ tumors was defined also by the smaller
number of ICSA than the MYCN− group (P = .0231; Figure W1B).
The most recurrent changes inMYCN+ cases were 17q gain (18 of 22,
82%) and 1p loss (17 of 22, 77%).
Correlation of Genomic Instability with Clinical Outcome
Five segmental genomic aberrations of MYCN− tumors revealed a
close association with the course of the disease: adverse clinical out-
come was associated with 1p loss (P = .009, Fisher exact test), 11p
gain (P = .010), 11q gain (P = .021), 17q gain (P = .002), and 19q
loss (P = .0005). As shown in Figure W2, these CNAs were negative
predictors of OS (P = .0008, P = .0110, P = .0185, P = .0055, and
P = .0001, respectively) and EFS (P = .0010, P = .0097, P = .0067,
P = .0067, and P = .0001, respectively).
Therefore, although we confirmed the inverse correlation between
MYCN amplification and 11q loss, in contrast to previous reports
[31,32], we found 11q loss (MRC: 11q23.1-q24.1) as one of the
most frequent abnormalities in MYCN− tumors of both long and
short survivors without any significant relationship with clinical out-
come (P = .3477 for OS and P = .2395 for EFS). Intriguingly, in our
cohort ofMYCN− tumors, 11q loss was significantly frequently associ-
ated with 11q gain (MCR: 11q13.1-q13.3) and/or 11p gain (MCR:
11p11.12-p12) in short survivors with respect to long survivors (10
of 24, 42% vs 6 of 41, 15%, P = .019 for 11q gain; 8 of 24, 42% vs
4 of 41, 15%, P = .024 for 11p gain). The 11q gain resulted a negative
predictor of poor survival. We argue that it may be because of the high
chromosome instability found in short survivors that leads, in case of
chromosome 11, to several chromosome breakpoints causing losses/
gains of different portions of short and long arms. We cannot exclude
the presence of isochromosome 11 [i.e., idic(11)(pter→q13.4::
q13.4→pter), idic(11)(pter→q14.1::q14.1→pter)] as result of 11p
and 11q arm rearrangements.
The predictive value of CNA on patients’ outcome was then eval-
uated by univariate and multivariate models within the cohort of all
91 patients analyzed by aCGH. The Kaplan-Meier curves confirmed
that 1p loss, 17q gain, and 19q loss were associated with a poorer
outcome (P values for the log-rank tests for OS and EFS were
<.04 for the three CNAs; Figure W3). The Cox regression analysis
(Table 1), after the adjustment for the effect ofMYCN amplification,
showed the predictive value on OS and EFS of 19q loss (P < .03) but
not of 1p loss and 17q gain likely because of the association between
these two CNAs andMYCN amplification. Because the role of 17q is
still somewhat controversial [33,34], it is noteworthy that the strat-
ified analysis using MYCN− tumors confirmed that 17q gain is inde-
pendently predictive of poor outcome (Figure W2).
Figure 2A plots the frequency of MYCN− samples with at least
one, two, or three whole chromosome changes, regardless of which
specific chromosome are affected. The distinction of the positive and
negative outcome groups was poor (Chi-square test, P > .2). Con-
versely, a significant distinction was obtained by counting samples
with at least two or three segmental chromosome changes (P =
.0340 and P = .0017, respectively; Figure 2B). The effect of further
changing the chromosome number threshold is demonstrated by the
ROC analysis (Figure 2C ). ROC and Kaplan-Meier curves (Fig-
ure 2D) showed that at least three segmental CNAs are needed to
Figure 1. Summary of aCGH results. (A) Bar chart and box-and-whisker graphs of the number of (B) numerical and (C) segmental CNAs
in the two groups of long and short survivors without MYCN amplification. (D) Bar chart and box-and-whisker graphs of the number of
(E) numerical and (F) segmental CNAs in the two groups of short survivors with and without MYCN amplification.
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discriminate (P = .0017) long from short survivors at the highest
sensitivity (95.8%) and specificity (51.2%).
In the cohort of all 91 patients analyzed by aCGH, both univariate
(Figure 3, A and B) and multivariate (Table 1) models confirmed the
predictive value of segmental CNA above the threshold on OS and
EFS (P = .0009 and P = .0003, respectively), regardless of other NB-
associated chromosomal aberrations, i.e., MYCN amplification, 1p
and 11q losses, and 17q gain. Accordingly, NBs with high number of
ICSA were associated with a poor prognosis (P < .005; Figure 3, C and
D). The prognostic impact of structural variations per chromosome
was independent of MYCN amplification, 1p loss, 11q loss, and 17q
gain in multivariate analyses (Table 1).
Identification of Region-Specific Candidate Genes by
Integration of aCGH and GE Data Sets
To determine the influence of chromosomal alterations on locus-
specific GE, we integrated the aCGH and transcriptome data sets.
We first focused on a gene-by-gene basis analyses of copy number
Figure 2. Histogram charts showing frequency of long and short survivors without MYCN amplification showing ≥1, ≥2, and ≥3
(A) numerical and (B) segmental CNAs. (C) Sensitivity and specificity in predicting survival based on different numbers of segmental
CNAs are above the thresholds defined by ROC curve. The point marked with dot represents the highest average of sensitivity and
specificity at the cutoff value of 3 (AUC = 0.785, Z statistic = 5.024, P < .0001). (D) Kaplan-Meier analysis for OS of 65 MYCN− NB
patients with ≥3 or <3 segmental CNAs.
Table 1. Cox Regression Analysis in 91 Stage 4 HR NB Patients.
Segmental CNA Covariate EFS OS
b SE* P Exp(b) Hazard Ratio (95%) CI† b SE* P Exp(b) Hazard Ratio (95%) CI†
1p loss MYCN ampl 0.638 0.369 .084 1.893 0.921 to 3.892 0.587 0.390 .133 1.798 0.839 to 3.849
11q loss MYCN ampl 0.515 0.349 .141 1.674 0.846 to 3.310 0.413 0.323 .201 1.512 0.805 to 2.840
17q gain MYCN ampl 0.529 0.434 .223 1.698 0.728 to 3.956 0.543 0.464 .242 1.722 0.696 to 4.257
19q loss MYCN ampl 1.49 0.449 .001 4.427 1.846 to 10.668 1.513 0.461 .001 4.542 1.849 to 11.153
≥3 CNA MYCN ampl 0.952 0.390 .015 2.592 1.211 to 5.547 1.015 0.414 .014 2.758 1.231 to 6.181
≥3 CNA 1p loss 0.701 0.416 .033 2.016 0.896 to 4.538 0.782 0.435 .038 2.185 0.934 to 5.109
≥3 CNA 11q loss 1.304 0.400 .001 3.685 1.688 to 8.044 1.383 0.425 .001 3.987 1.740 to 9.137
≥3 CNA 17q gain 0.891 0.420 .034 2.437 1.073 to 5.531 0.936 0.448 .037 2.550 1.064 to 6.110
ICSA MYCN ampl 0.910 0.249 .0003 2.485 1.526 to 4.045 0.995 0.262 .0002 2.705 1.621 to 4.513
ICSA 1p loss 0.730 0.261 .005 2.075 1.246 to 3.455 0.818 0.272 .003 2.266 1.332 to 3.855
ICSA 11q loss 1.268 0.275 <.0001 3.553 2.078 to 6.073 1.359 0.287 <.0001 3.892 2.225 to 6.809
ICSA 17q gain 0.803 0.257 .002 2.233 1.353 to 3.686 0.859 0.273 .002 2.363 1.388 to 4.024
Hazard ratios were adjusted for MYCN amplification, 1p loss, 11q loss, and 17q gain.
*SE, standard error.
†CI, confidence interval.
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and expression data throughout the genome of 51MYCN−NBs (21
long and 30 short survivors). Tumors from the two clinical sub-
groups differed in 169 genes (Table W2). Transcription levels were
correlated to genomic patterns for 36 STGs, representing 22% of
the genes significantly associated with adverse outcome. The STGs
were located on chromosomes 1p, 3p, 11q, and 17q (Table W3).
Functional annotation highlighted GO terms mostly associated with
cell junction, neuritogenesis, and Rho GTPase–mediated signal
transduction (Table W4).
Then, we combined the aCGH and GE data sets to focus only on
the genes restricted to MCRs for which the expression was affected
by aberrant copy number variations. We selected the 646 probe sets
mapping at MCRs of the CNA significantly associated with adverse
outcome in MYCN− tumors. Most patterns of gene amplification
and increased GE were concordant, that is, a significant fraction of
the amplified genes were correspondingly highly expressed. Such
concordance was also found for part of the genes located in losses.
The “correlated study” showed that DNA copy number influenced
GE across a range of MCRs corresponding to 57 correlated genes
that were differentially expressed between tumors from the two clin-
ical subgroups and concordant with MCR patterns (Figure 4A and
Table W5). Fifty-two genes (91%) were overexpressed in NBs of
short survivors and 77% of them mapped at 11q gain (MCR:
11q12-q13.5). The most enriched GO terms were mRNA processing
(AIP, DRAP1, SART1, and SF3B2) and cell cycle process (ARL2,
SAC3D1, SSSCA1, CDCA5, PSMC3, PSMD13, and SART1).
Intriguingly, 11p15.5 gain was found associated with overexpression
of HRAS gene, known to be involved in activation of cell prolifera-
tion. Moreover, the deletions of 1p36 and 19q13.43 affected expres-
sion of three genes (CAMTA1, PRDM2, and ZSCAN22) involved in
regulation of transcription (Table W5).
Transcription profile differences associated with MYCN overexpres-
sion were highlighted by comparing 20 MYCN+ and 30 MYCN−
tumors of short survivors (Table W2). The “targeted study” showed
that DNA copy number directly influenced expression of 39 STGs
representing 27% of the genes significantly associated with MYCN
amplification and located on chromosomes 1p, 2p, 3p, 11q, and 17q
(TableW3). The 31 STGs (56%) down-expressed in regions frequently
lost in MYCN+ tumors were related to angiogenesis (VEGFB), cell
adhesion (CDC42 and PIK3CD), neuritogenesis of NB cells (CDC42)
[35], and regulation of small GTPase-mediated signal transduction
(CDC42, ASAP3, ARHGEF10L, and MFN2; Tables W3 and W4).
Finally, we selected 591 probe sets mapping at gained or lost MCRs
significantly associated withMYCN amplification (Figure 4B). GE anal-
ysis identified 169 genes differentially expressed between the two groups
of NBs (Table W5). A significant number of amplified and correspond-
ingly highly expressed genes inMYCN+ tumors were active in prolifer-
ative (i.e., CUL5, H2AFX, MRE11A, RBM7, and ZW10 mapping at
11q21-q23.3) and transcriptional processes (ZNF350, ZNF135,TRIM28,
ZNF473, RUVBL2, ZNF587, ZNF525, and CRX at 19q13.3-q13.4).
Conversely, down-expressed correlated genes in MYCN+ NBs are
mostly associated with apoptosis (HRAS, CD44, MADD, ILK,
SMPD1, MAPK8IP1, and APBB1), cell-matrix and cell-cell adhesion
(CD44, FXC1, ILK, and PARVA), and neuronal differentiation
(CD44, TH, ILK, and APBB1) pathways at 11p11.2-pter. Interest-
ingly, MYCN oncogene overexpression was also associated with up-
regulation of its neighbor genes (DDX1, FAM49A, and NAG ) and
of MRE11A target gene. Moreover, the “correlated study” showed the
decrease of DDB2 expression, one of the known genes directly down-
regulated byMYCN, and RHOG, a member of the Rac subfamily of the
Rho family of small G proteins. Finally,MYCN+ NBs showed a lower
expression of two functionally interesting genes at 11q13.1-q23, namely,
Figure 3. Kaplan-Meier OS and EFS estimates in 91 HR NB patients according to the segmental CNA threshold (A, B) and the presence
of ICSA (C, D).
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Figure 4. Correlated studies. Hierarchically clustered heat maps of probe sets mapped on MCR with significant differential expression in
(A)MYCN− tumors from long survivors versus MYCN− tumors from short survivors and (B)MYCN− tumors from short survivors versus
MYCN+ tumors from short survivors. Each color patch represents the expression level of genes (row) in that sample (column), with a
continuum of expression levels from bright green (lowest) to bright red (highest).
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RARRES3, which encodes a retinoic acid receptor responder, and
BRMS1, which is a cancer metastasis suppressor gene involved in breast
cancer progression.
Discussion
In the present paper, we report integrative DNA copy number and
GE analyses in HR metastatic NB. During the last decade, several
articles reported cytogenetic aberrations able to affect abnormal GE
profiles in NB [6–19]. Moreover, large-scale genomic imbalances play
a role in the dysregulation of miRNA expression [36]. Correlations of
specific patterns of copy number alterations with patient survival have
been identified in a broad set of NB samples covering all risk catego-
ries. Differently, here we focused on stage 4 HR NB with follow-up
for at least 5 years, and this is the largest study for this HR subtype.
It is noteworthy that although tumor specimens were collected
from patients who were diagnosed with a primary NB between 1988
and 2006, no significant differences over time were recorded in OS of
patients in relation to enrollment year. This is in agreement with the
recent report by Haupt et al. [4] showing that no OS improvement was
seen for stage 4 patients in 1985 to 2005 period of diagnosis.
First, we excluded tumors with MYCN oncogene amplification.
The resulting association between average of segmental aberrations
and fatal outcome was therefore not affected by MYCN bias. Our
analysis indicates that patients with CNA < 3 in their tumors have
a significantly better prognosis with respect to those with a higher
number of chromosomal alterations, including ICSA, both in terms
of EFS and OS. This supports speculations of multiple molecular
subtypes of NB [13,37]. The significant higher chromosome insta-
bility in tumors of short survivors may be because of a loss of func-
tion of mitotic checkpoint control mechanisms [38].
Then, we highlighted CNA associated with MYCN amplification
in patients with fatal outcome. Our data show two subtypes of NBs
with different genomic profiles: whereas MYCN+ cases involve 2p
gain and often 11q loss and 17q gain but very few other segmental
aberrations, the MYCN− tumors generally have a complex pattern of
CNA, mainly focused on chromosomes 1, 2, 3, 11, 17, and 19. This
higher DNA instability observed in MYCN− NBs may explain why
children older than 12 months of age with a stage 4 tumor have a
poor outcome independently by MYCN status.
As regarding transcript analysis, we used a dual strategy that delin-
eated genes with either significantly concordant or correlated changes
in copy number and in expression. The major advantage of choosing
such approach was that it bypasses limitations because of the small
number of cases and intertumor heterogeneity. Moreover, such strat-
egy allowed us to delineate two sets of genes with distinct biologic
relevance. The STGs show expression alterations in almost all sam-
ples, and therefore, they correspond to changes essential for aggres-
siveness and tumor progression. In contrast, the genes identified by
the “correlated study” have an expression directly linked to the DNA
copy number status, representing functionally significant events asso-
ciated with chromosome gains and losses and related to different
clinical subclasses of stage 4 HR NBs.
The widespread homogeneous STG down-expression in tumors
from short survivors involves cell adhesion processes, angiogenesis,
and neuron differentiation defect. In particular, the disruption of neu-
ronal differentiation mirrors a more primitive phenotype in aggressive
NBs, regardless MYCN amplification. Functional annotation analyses
show that the two clusters of long and short survivors are mainly
dependent on deregulation of STGs involved in Rho/Ras-mediated
signal transduction. The Rho family of small GTPases, in particular
Rho, Rac (i.e., RhoG), and CDC42, are important regulators of sig-
naling pathways controlling cell morphology, migration, and cell cycle
progression [39–41]. Recent studies using knockout mouse models
provided evidence of the primary role played by Rho signaling during
the development of the nervous system [42]. As with all small G pro-
teins, Rho family is able to signal to downstream effectors when bound
to guanosine triphosphate (GTP) and inactive when bound to guano-
sine diphosphate (GDP). Among the proteins interacting with Rho to
regulate GTP/GDP loading, guanine nucleotide exchange factors
(GEFs) facilitate the exchange of GDP for GTP so as to induce sub-
sequent Rho-mediated signaling, and GTPase-activating proteins pro-
mote GTP hydrolysis, thus terminating the Rho cascade. There are a
number of GEFs reported to interact with RhoG. Well-characterized
GEFs include TRIO that is able to promote nucleotide exchange on
RhoG, Rac, and RhoA [43,44]. Activation of RhoG by TRIO has been
shown to promote nerve growth factor (NGF)-induced neurite out-
growth in PC12 cells [45] and to coordinate cell-matrix and cytoskel-
etal rearrangements necessary for cell migration and cell growth. Our
“targeted study” shows the involvement of deregulation of Rho GTPase
pathway and genes related to cell motility in loss of cell cycle control
and progression of tumor, regardless MYCN status. On the one hand,
this explains the increase of tumor chromosome instability in patients
with fatal outcome andwhyMYCN gene amplification is not a prognos-
tic marker in stage 4 patients. However, we argue that defects in regu-
lation of neuritogenesis represent important tumor-driving events in
HRNBs, as recently reported byMolenaar et al. [46]. Actually, our find-
ings indicate that tumors withoutMYCN amplification but with dereg-
ulation of Rho GTPase signaling genes functioning in neuritogenesis
mostly are aggressive HR NBs. Intriguingly, in MYCN+ tumors, the
inhibition of neuritogenesis may be because of theMYCN-driven down-
regulation of CDC42 and RHOG expression.
Moreover, high-level expression of angiogenic factors in tumors of short
survivors confirms that angiogenic factors are associated with advanced
tumor stage in human NB [47]. Notably, our data show that expression
level of VEGFB was not associated withMYCN amplification. Therefore,
one may speculate that up-regulation of VEGFB is a mechanism used
by MYCN-aggressive NB tumors to attract vascular endothelial cells.
The “correlated study” highlights other signatures related to reg-
ulatory mechanisms for NB progression, such as proliferative and
transcriptional processes, and specific MYCN-driven pathways. For
example, inMYCN+ tumors, the expression of cell-matrix and cell-cell
adhesion genes is significantly suppressed. Recent experimental results
indicate that changes in the expression or function of cell adhesion
molecules can contribute to tumor progression and promote tumor
invasion and metastasis [48]. Finally, the top-ranked enriched sets in
MYCN+ tumors contain MYCN-responsive genes and genes involved
in ribosome biogenesis and assembly, as recently reported [49].
In conclusion, children with less than three segmental CNA in their
tumor represent a molecularly defined subgroup with a high survival
probability within the current HR group of patients, regardlessMYCN
status. The complex genomic pattern is a prognostic marker indepen-
dent of NB-associated chromosomal aberrations, i.e.,MYCN oncogene
amplification, 1p and 11q losses, and 17q gain. Integrative analysis of
genomic and expression signatures demonstrated that fatal outcome is
mainly associated with loss of cell cycle control and deregulation of
Rho GTPase pathway. Moreover, the MYCN amplification mainly
drives the disruption of neuritogenesis and the reduction of cell
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adhesion process involved in tumor invasion and metastasis. Further
validation studies are warranted to establish this as a risk stratification
for patients.
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Figure W1. Box-and-whisker graphs of the number of ICSAs in the two groups of (A) long and short survivors without MYCN amplifi-
cation and (B) short survivors with and without MYCN amplification.
Figure W2. Kaplan-Meier OS and EFS estimates in 54MYCN− tumor patients according to (A, B) 1p loss, (C, D) 11p gain, (E, F) 11q gain,
(G, H) 17q gain, and (I, J) 19q loss.
Figure W3. Kaplan-Meier OS and EFS estimates in 91 HR NB patients according to (A, B) 1p loss, (C, D) 11p gain, (E, F) 11q gain, (G, H) 17q
gain, and (I, J) 19q loss.
Table W3. List of Genes Selected by the “Targeted Study” of MYCN− Tumors from Long and Short Survivors and of MYCN− and MYCN+ Tumors from Short Survivors.
Gene Name Chromosome Map Description Difference of Log2 Fold Change (LS − SS)
ACCN1 17q12 Amiloride-sensitive cation channel 1, neuronal 0.53
AGRIN 1p36.33 Agrin 0.34
ALG9 11q23 Asparagine-linked glycosylation 9 homolog (Saccharomyces cerevisiae,
α-1,2-mannosyltransferase)
0.09
BACE1 11q23.2-q23.3 β-Site APP-cleaving enzyme 1 0.43
BARX2 11q25 BARX homeobox 2 0.11
C17orf63 17q11.2 Chromosome 17 open reading frame 63 0.47
C3orf35 3p22.2 Chromosome 3 open reading frame 35 0.19
CAMTA1 1p36.31-p36.23 Calmodulin-binding transcription activator 1 0.51
CLNS1A 11q13.5-q14 Chloride channel, nucleotide-sensitive, 1A 0.43
DCP1A 3p21.1 DCP1 decapping enzyme homolog A (S. cerevisiae) 0.34
DIRAS3 1p31 DIRAS family, GTP-binding RAS-like 3 1.60
EAF1 3p24.3 ELL-associated factor 1 0.08
ERC2 3p14.3 ELKS/RAB6-interacting/CAST family member 2 0.77
GDPD5 11q13.4-q13.5 Glycerophosphodiester phosphodiesterase domain containing 5 0.55
GRIA4 11q22 Glutamate receptor, ionotrophic, AMPA 4 0.21
ITSN2 2pter-p25.1 Intersectin 2 0.27
KCNC4 1p21 Potassium voltage-gated channel, Shaw-related subfamily, member 4 0.12
LOC116236 17q11.2 Hypothetical protein LOC116236 0.42
MAGI1 3p14.1 Membrane-associated guanylate kinase, WW and PDZ domain containing 1 0.63
MPP3 17q21.31 Membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) 0.42
NKAIN1 1p35.2 Na+/K+ transporting ATPase interacting 1 0.61
PGM2L1 11q13.4 Phosphoglucomutase 2–like 1 1.17
PRDM2 1p36.21 PR domain containing 2, with ZNF domain 0.27
RAB30 11q12-q14 RAB30, member RAS oncogene family 0.31
RAB6A 11q13.3 RAB6B, member RAS oncogene family 0.71
RBMS3 3p24-p23 RNA binding motif, single stranded interacting protein 0.76
REEP1 2p11.2 Receptor accessory protein 1 0.84
ROBO1 3p12 Roundabout, axon guidance receptor, homolog 1 (Drosophila) 0.95
ROBO2 3p12.3 Roundabout, axon guidance receptor, homolog 2 (Drosophila) 0.96
RSF1 11q14.1 Remodeling and spacing factor 1 0.36
SHANK2 11q13.3 SH3 and multiple ankyrin repeat domains 2 0.52
SPAG9 17q21.33 Sperm-associated antigen 9 0.6
TRAK1 3p25.3-p24.1 Trafficking protein, kinesin binding 1 0.20
UBE4B 1p36.3 Ubiquitination factor E4B (UFD2 homolog, yeast) 0.25
VAMP3 1p36.23 Vesicle-associated membrane protein 3 (cellubrevin) 0.72
ZNF445 3p21.32 Zinc finger protein 445 0.08
Gene Name Chromosome Map Description Difference of Log2 Fold Change
(SS_MYCN− − SS_MYCN+)
AKIRIN1 1p34.3 Akirin 1 0.47
ARHGEF10L 1p36.13 Rho GEF 10-like 0.63
ASAP3 1p36.12 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 0.54
CDC42 1p36.1 Cell division cycle 42 (GTP-binding protein, 25 kDa) 0.61
CLCN6 1p36 Chloride channel 6 0.79
CLSTN1 1p36.22 Calsyntenin 1 0.77
CTNNBIP1 1p36.22 Catenin, β interacting protein 1 0.74
DDX1 2p24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 −2.55
DNAJC8 1p35.3 DnaJ (Hsp40) homolog, subfamily C, member 8 0.67
FAM54B 1p36.11 Family with sequence similarity 54, member B 0.26
FKBP2 11q13.1-q13.3 FK506 binding protein 2, 13 kDa 0.74
HK2 2p13 Hexokinase 2 −1.27
HMGCL 1p36.1-p35 3-Hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 0.75
HP1BP3 1p36.12 Heterochromatin protein 1, binding protein 3 0.44
HPCAL4 1p34.2 Hippocalcin like 4 1.30
KIAA0090 1p36.13 KIAA0090 0.56
KIAA1310 2p12-p11.2 KIAA1310 −0.70
LOC100128003 1p36.33 Hypothetical protein LOC100128003 0.43
LOC643837 1p36.33 Hypothetical LOC643837 0.55
LRPPRC 2p21 Leucine-rich PPR-motif containing −0.65
LZIC 1p36.22 Leucine zipper and CTNNBIP1 domain containing 0.72
MFN2 1p36.22 Mitofusin 2 0.88
MSH2 2p22-p21 MutS homolog 2, colon cancer, nonpolyposis type 1 (Escherichia coli) −0.66
MTHFD2 2p13.1 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2,
methenyltetrahydrofolate cyclohydrolase
−1.11
MYCN 2p24.1 V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) −4.34
PIGV 1p36.11 Phosphatidylinositol glycan anchor biosynthesis, class V 0.54
PIK3CD 1p36.2 Phosphoinositide 3-kinase, catalytic, delta polypeptide 0.60
PINK1 1p36 PTEN-induced putative kinase 1 0.54
PTP4A2 1p35 Protein tyrosine phosphatase type IVA, member 2 0.88
RCAN3 1p35.3-p33 RCAN family member 3 1.57
ROM1 11q13 Retinal outer segment membrane protein 1 1.36
Table W4. The Most Significantly (P .05) Enriched GO Biologic Process (GOBP) Terms in Genes Selected by the “Targeted Study” ofMYCN− Tumors from Long and Short Survivors and ofMYCN−
and MYCN+ Tumors from Short Survivors.
GOBP Term P Genes
“Targeted study” of MYCN− tumors from long and short survivors
GO:0030424∼axon 4.40E−03 ROBO1, BACE1, ROBO2, GRIA4
GO:0043005∼neuron projection 5.40E−03 ROBO1, BACE1, ROBO2, ERC2, GRIA4
GO:0033267∼axon part 5.75E−03 ROBO1, ROBO2, GRIA4
GO:0005886∼plasma membrane 1.23E−02 CLNS1A, KCNC4, MAGI1, MPP3, NKAIN1, GRIA4, SHANK2, ACCN1,
RAB30, DIRAS3, ROBO1, BACE1, ROBO2, VAMP3, ERC2
GO:0030673∼axolemma 1.26E−02 ROBO1, ROBO2
GO:0032589∼neuron projection membrane 1.68E−02 ROBO1, ROBO2
GO:0030054∼cell junction 2.23E−02 MAGI1, VAMP3, ERC2, GRIA4, SHANK2
IPR001806:Ras GTPase 2.76E−02 RAB30, DIRAS3, RAB6A
GO:0009986∼cell surface 3.61E−02 ROBO1, MPP3, BACE1, ROBO2
GO:0045202∼synapse 3.80E−02 VAMP3, ERC2, GRIA4, SHANK2
IPR005225:Small GTP-binding protein 4.07E−02 RAB30, DIRAS3, RAB6A
GO:0065003∼macromolecular complex assembly 4.13E−02 CLNS1A, SPAG9, RSF1, MAGI1, VAMP3
GO:0031256∼leading edge membrane 4.75E−02 ROBO1, ROBO2
GO:0050772∼positive regulation of axonogenesis 4.88E−02 ROBO1, ROBO2
GO:0043933∼macromolecular complex subunit organization 5.06E−02 CLNS1A, SPAG9, RSF1, MAGI1, VAMP3
“Targeted study” of MYCN− versus MYCN+ tumors from short survivors
GO:0046578∼regulation of Ras protein signal transduction 4.52E−02 MFN2, ASAP3, ARHGEF10L
Table W3. (continued )
Gene Name Chromosome Map Description Difference of Log2 Fold Change
(SS_MYCN− − SS_MYCN+)
RPA2 1p35 Replication protein A2, 32 kDa 0.65
SLC30A3 2p23.3 Solute carrier family 30 (zinc transporter), member 3 −1.06
SSU72 1p36.33 SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae) 0.55
STX12 1p35-p34.1 Syntaxin 12 0.77
SYNC 1p34.3-p33 syncoilin, intermediate filament protein 0.73
TAF12 1p35.3 TAF12 RNA polymerase II, TATA box binding protein–associated factor, 20 kDa 0.64
TMEM50A 1p36.11 Transmembrane protein 50A 0.66
VEGFB 11q13 Vascular endothelial growth factor B 0.55
